Marco Moschini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3872380/publications.pdf

Version: 2024-02-01

228 papers	4,073 citations	147801 31 h-index	197818 49 g-index
231 all docs	231 docs citations	231 times ranked	4453 citing authors

#	Article	IF	Citations
1	More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. European Urology, 2015, 67, 212-219.	1.9	178
2	Characteristics and clinical significance of histological variants of bladder cancer. Nature Reviews Urology, 2017, 14, 651-668.	3.8	147
3	A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. European Urology, 2016, 69, 788-794.	1.9	140
4	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€"An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	1.9	132
5	Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. European Urology, 2019, 75, 649-658.	1.9	82
6	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. European Urology, 2017, 71, 886-893.	1.9	77
7	Extent of lymph node dissection at nephrectomy affects cancerâ€specific survival and metastatic progression in specific subâ€categories of patients with renal cell carcinoma (<scp>RCC</scp>). BJU International, 2014, 114, 210-215.	2.5	69
8	Comparing longâ€term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU International, 2016, 117, 604-610.	2.5	68
9	Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 335-341.	1.6	66
10	Critical Review of Outcomes from Radical Cystectomy: Can Complications from Radical Cystectomy Be Reduced by Surgical Volume and Robotic Surgery?. European Urology Focus, 2016, 2, 19-29.	3.1	65
11	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urologyâ€"Young Academic Urologists and theÂUpper Tract Urothelial Carcinoma Collaboration. BJU International, 2018, 121, 252-259.	2.5	61
12	Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. European Urology, 2021, 79, 44-53.	1.9	61
13	The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. European Urology, 2016, 69, 1142-1148.	1.9	60
14	Natural History of Clinical Recurrence Patterns of Lymph Nodeâ€"Positive Prostate Cancer After Radical Prostatectomy. European Urology, 2016, 69, 135-142.	1.9	58
15	External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. European Urology, 2019, 75, 319-328.	1.9	57
16	Low-risk Prostate Cancer: Identification, Management, and Outcomes. European Urology, 2017, 72, 238-249.	1.9	55
17	Early Postoperative Radiotherapy is Associated with Worse Functional Outcomes in Patients with Prostate Cancer. Journal of Urology, 2017, 197, 669-675.	0.4	55
18	Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. BMC Medicine, 2016, 14, 67.	5.5	53

#	Article	IF	Citations
19	Differences in trends in the use of robotâ€assisted and open radical cystectomy and changes over time in periâ€operative outcomes among selected centres in North America and Europe: an international multicentre collaboration. BJU International, 2019, 124, 656-664.	2.5	53
20	Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis. Clinical Genitourinary Cancer, 2017, 15, e793-e800.	1.9	51
21	Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience. European Journal of Surgical Oncology, 2016, 42, 735-743.	1.0	49
22	Lymphocyteâ€toâ€monocyte ratio and neutrophilâ€toâ€lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. Journal of Surgical Oncology, 2017, 115, 455-461.	1.7	46
23	Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. Translational Andrology and Urology, 2016, 5, 735-744.	1.4	43
24	Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. World Journal of Urology, 2017, 35, 1541-1547.	2.2	41
25	Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. European Urology Oncology, 2020, 3, 94-101.	5.4	41
26	Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 150.e9-150.e15.	1.6	40
27	Effect of Allogeneic Intraoperative Blood Transfusion on Survival in Patients Treated With Radical Cystectomy for Nonmetastatic Bladder Cancer: Results From a Single High-Volume Institution. Clinical Genitourinary Cancer, 2015, 13, 562-567.	1.9	37
28	Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup. Journal of Urology, 2016, 195, 1773-1778.	0.4	37
29	Usefulness of pT1 substaging in papillary urothelial bladder carcinoma. Diagnostic Pathology, 2016, 11, 6.	2.0	33
30	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World Journal of Urology, 2017, 35, 251-259.	2.2	33
31	Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. Clinical Genitourinary Cancer, 2017, 15, e267-e273.	1.9	33
32	Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. European Urology Focus, 2020, 6, 1233-1239.	3.1	33
33	Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma. Anticancer Research, 2014, 34, 3225-30.	1.1	33
34	Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder. World Journal of Urology, 2018, 36, 231-240.	2.2	32
35	Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. BJU International, 2019, 124, 738-745.	2.5	32
36	Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer. European Urology Focus, 2018, 4, 87-93.	3.1	31

#	Article	IF	Citations
37	Prognostic role of N-cadherin expression in patients with nonâ€“muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 264-271.	1.6	30
38	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Nonâ€“muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2017, 15, e755-e764.	1.9	29
39	Impact of stage migration and practice changes on highâ€risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades. BJU International, 2016, 117, 740-747.	2.5	28
40	Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism. Scientific Reports, 2017, 7, 42157.	3.3	28
41	Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies. Journal of Urology, 2018, 199, 1149-1157.	0.4	28
42	The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. World Journal of Urology, 2022, 40, 1617-1628.	2.2	28
43	Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy. European Urology, 2016, 69, 193-196.	1.9	27
44	Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients. Clinical Genitourinary Cancer, 2017, 15, e603-e607.	1.9	27
45	Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. European Urology, 2021, 80, 507-515.	1.9	27
46	Predicting survival of men with recurrent prostate cancer after radical prostatectomy. European Journal of Cancer, 2016, 54, 27-34.	2.8	26
47	Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 77.e1-77.e7.	1.6	26
48	The impact of preoperative nutritional status on post-surgical complication and mortality rates in patients undergoing radical cystectomy for bladder cancer: a systematic review of the literature. World Journal of Urology, 2021, 39, 1045-1081.	2.2	26
49	Pelvic Lymph Node Dissection in Prostate Cancer: Indications, Extent and Tailored Approaches. Urologia, 2017, 84, 9-19.	0.7	25
50	Histological variants in non-muscle invasive bladder cancer. Translational Andrology and Urology, 2019, 8, 34-38.	1.4	25
51	Oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: an updated meta-analysis. World Journal of Surgical Oncology, 2021, 19, 129.	1.9	25
52	Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy. European Urology Focus, 2018, 4, 245-251.	3.1	24
53	Oncological predictive value of the 2004 World Health Organisation grading classification in primary <scp>T1</scp> nonâ€muscleâ€invasive bladder cancer. A step forward or back?. BJU International, 2015, 115, 267-273.	2.5	23
54	Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. Abdominal Radiology, 2018, 43, 2391-2399.	2.1	23

#	Article	IF	Citations
55	18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosisâ€"A Multicenter Retrospective Study. Cancers, 2019, 11, 700.	3.7	23
56	The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Twoâ€Center Validation Study. Prostate, 2017, 77, 263-273.	2.3	22
57	Frailty impact on postoperative complications and early mortality rates in patients undergoing radical cystectomy for bladder cancer: a systematic review. Arab Journal of Urology Arab Association of Urology, 2021, 19, 9-23.	1.5	22
58	Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection. Prostate, 2015, 75, 1484-1491.	2.3	21
59	Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 57.e1-57.e7.	1.6	21
60	The Impact of Perioperative Blood Transfusion on Survival of Bladder Cancer Patients Submitted to Radical Cystectomy: Role of Anemia Status. European Urology Focus, 2016, 2, 86-91.	3.1	20
61	Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 256.e7-256.e13.	1.6	20
62	Bacillus Calmette-GuÃ©rin unresponsiveness in non-muscle-invasive bladder cancer patients: what the urologists should know. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 17-30.	3.9	20
63	Are all grade group 4 prostate cancers created equal? Implications for the applicability of the novel grade grouping. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 461.e7-461.e14.	1.6	19
64	Prognostic Value of Serum Cholinesterase in Nonâ€"muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e1123-e1132.	1.9	19
65	Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis. Clinical Genitourinary Cancer, 2020, 18, 78-87.	1.9	19
66	Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2021, 4, 580-593.	5.4	19
67	How to optimally manage elderly bladder cancer patients?. Translational Andrology and Urology, 2016, 5, 683-691.	1.4	18
68	Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. World Journal of Urology, 2018, 36, 639-644.	2.2	18
69	The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 533.e1-533.e10.	1.6	17
70	Validation of the American Society for Reproductive Medicine guidelines/recommendations in white European men presenting for couple's infertility. Fertility and Sterility, 2016, 106, 1076-1082.e1.	1.0	17
71	Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. European Urology, 2019, 75, 817-825.	1.9	17
72	Importance of prostate volume in the stratification of patients with intermediateâ€risk prostate cancer. International Journal of Urology, 2015, 22, 555-561.	1.0	16

#	Article	IF	Citations
73	Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 59.e15-59.e22.	1.6	16
74	Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 307.e9-307.e14.	1.6	16
75	Elevated preoperative neutrophilâ€“lymphocyte ratio predicts upgrading at radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2018, 21, 100-105.	3.9	16
76	Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. European Urology Oncology, 2018, 1, 169-175.	5.4	16
77	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. BJU International, 2022, 129, 182-193.	2.5	16
78	Intracorporeal versus extracorporeal urinary diversion in robot-assisted radical cystectomy: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2021, 26, 1587-1599.	2.2	16
79	Available evidence on HIFU for focal treatment of prostate cancer: a systematic review. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2022, 48, 263-274.	1.5	16
80	Erectile Function Recovery After Nerve-Sparing Radical Prostatectomy for Prostate Cancer: Is Back to Baseline Status Enough for Patient Satisfaction?. Journal of Sexual Medicine, 2016, 13, 669-678.	0.6	15
81	Perioperative Allogenic Blood Transfusion in Renal Cell Carcinoma: Risk Factors and Effect on Long-term Outcomes. Clinical Genitourinary Cancer, 2017, 15, e421-e427.	1.9	15
82	Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study. European Urology Focus, 2018, 4, 68-74.	3.1	15
83	Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs. Clinical Genitourinary Cancer, 2022, 20, 198.e1-198.e9.	1.9	15
84	Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates. European Journal of Pharmacology, 2014, 744, 42-51.	3.5	14
85	A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy. World Journal of Urology, 2016, 34, 207-213.	2.2	14
86	Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 528.e1-528.e5.	1.6	14
87	Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2017, 15, e1039-e1045.	1.9	14
88	Incidence and Predictors of 30-Day Readmission After Robot-Assisted Radical Prostatectomy. Clinical Genitourinary Cancer, 2017, 15, 67-71.	1.9	14
89	Prediction tools in non-muscle invasive bladder cancer. Translational Andrology and Urology, 2019, 8, 39-45.	1.4	14
90	Stratification of Intermediate-risk Nonâ€“muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies. European Urology Focus, 2020, 7, 566-573.	3.1	14

#	Article	IF	Citations
91	Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 106.e11-106.e19.	1.6	14
92	The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 151.e17-151.e23.	1.6	13
93	Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e73-e78.	1.9	13
94	Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. Journal of Clinical Medicine, 2019, 8, 1192.	2.4	13
95	Development of a New Comorbidity Assessment Tool for Specific Prediction of Perioperative Mortality in Contemporary Patients Treated with Radical Cystectomy. Annals of Surgical Oncology, 2019, 26, 1942-1949.	1.5	13
96	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. World Journal of Urology, 2021, 39, 443-451.	2.2	13
97	Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. European Urology Focus, 2022, 8, 491-497.	3.1	13
98	Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2017, 35, 1073-1080.	2.2	12
99	Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. Bladder Cancer, 2017, 3, 161-169.	0.4	12
100	Association between Inflammatory Potential of Diet and Bladder Cancer Risk: Results of 3 United States Prospective Cohort Studies. Journal of Urology, 2019, 202, 484-489.	0.4	12
101	Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis. Cancers, 2022, 14, 887.	3.7	12
102	What is the Need for Prostatic Biomarkers in Prostate Cancer Management?. Current Urology Reports, 2015, 16, 70.	2.2	11
103	Lymph node dissection for renal cell carcinoma. Current Opinion in Urology, 2016, 26, 424-431.	1.8	11
104	Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. Urology, 2016, 88, 97-103.	1.0	11
105	Diagnosis and management of spermatic cord tumors. Current Opinion in Urology, 2017, 27, 76-79.	1.8	11
106	Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study. World Journal of Urology, 2018, 36, 1417-1422.	2.2	11
107	Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 602.e11-602.e19.	1.6	11
108	The effectiveness of multiparametric magnetic resonance imaging in bladder cancer (Vesical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 T Urology, 2020, 18, 67-71.	1.5	11

#	Article	IF	Citations
109	Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-GuÃ©rin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. European Urology Focus, 2022, 8, 1270-1277.	3.1	11
110	Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors. European Urology Oncology, 2022, 5, 30-41.	5.4	11
111	Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma. European Urology Oncology, 2022, 5, 451-459.	5.4	11
112	Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience. Clinical Genitourinary Cancer, 2016, 14, e341-e346.	1.9	10
113	Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 460.e1-460.e8.	1.6	10
114	Longâ€term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy. BJU International, 2017, 120, 69-75.	2.5	10
115	Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 158.e1-158.e6.	1.6	10
116	Role of serum cholinesterase in patients treated with salvage radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 123-129.	1.6	10
117	Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. Clinical Genitourinary Cancer, 2019, 17, 72-78.e4.	1.9	10
118	Longâ€term functional and oncological outcomes of nerveâ€sparing and prostate capsuleâ€sparing cystectomy: a singleâ€centre experience. BJU International, 2020, 125, 253-259.	2.5	10
119	The impact of hormones and reproductive factors on the risk of bladder cancer in women: results from the Nursesâ€™ Health Study and Nursesâ€™ Health Study II. International Journal of Epidemiology, 2020, 49, 599-607.	1.9	10
120	Ureteral and urethral recurrence after radical cystectomy: a systematic review. Current Opinion in Urology, 2020, 30, 441-448.	1.8	10
121	Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 180-190.	1.6	10
122	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. European Urology Focus, 2022, 8, 761-768.	3.1	10
123	Enhanced recovery after surgery (ERAS) in radical cystectomy patients: from consensus to evidences. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 655-657.	1.5	10
124	Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After RadicalÂCystectomy. Clinical Genitourinary Cancer, 2017, 15, e681-e688.	1.9	9
125	Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?. Urologia Internationalis, 2019, 102, 269-276.	1.3	9
126	Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, 7-14.e3.	1.9	9

#	Article	IF	Citations
127	Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer. World Journal of Urology, 2020, 38, 2501-2511.	2.2	9
128	Comparing Perioperative Complications Between Laparoscopic and Robotic Radical Cystectomy for Bladder Cancer. Journal of Endourology, 2020, 34, 1033-1040.	2.1	9
129	Biomarkers predicting oncological outcomes of high-risk non-muscle-invasive bladder cancer. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 265-278.	3.9	9
130	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration. World Journal of Urology, 2022, 40, 1167-1174.	2.2	9
131	Systematic Review: The Learning Curve for Robot-Assisted Radical Cystectomyâ€"What Do We Know?. Journal of Endourology, 2022, , .	2.1	9
132	Characterization of Late Recurrence After Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. Urology, 2017, 106, 119-124.	1.0	8
133	Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer. Urologia Internationalis, 2017, 98, 290-297.	1.3	8
134	The surgical management of patients with clinical stage T4 bladder cancer: A single institution experience. European Journal of Surgical Oncology, 2017, 43, 808-814.	1.0	8
135	Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer. Expert Review of Anticancer Therapy, 2019, 19, 739-755.	2.4	8
136	Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 179.e1-179.e7.	1.6	8
137	Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. European Urology, 2020, 78, 489-491.	1.9	8
138	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e5-235.e14.	1.6	8
139	Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis. Cancers, 2021, 13, 2496.	3.7	8
140	Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. European Urology Focus, 2022, 8, 752-760.	3.1	8
141	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Minerva Urology and Nephrology, 2021, , .	2.5	8
142	Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 273.e11-273.e20.	1.6	8
143	Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer. Clinical Genitourinary Cancer, 2016, 14, e245-e250.	1.9	7
144	Preoperative anemia is associated with disease recurrence and progression in patients with nonâ€"muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 113.e9-113.e14.	1.6	7

#	Article	IF	Citations
145	Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer. European Urology Focus, 2018, 4, 834-841.	3.1	7
146	Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. European Urology Focus, 2021, 7, 1067-1074.	3.1	7
147	Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. World Journal of Urology, 2021, 39, 1947-1953.	2.2	7
148	Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 806-815.	1.6	7
149	Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 471-479.	1.6	7
150	Comparative Outcomes of Primary Versus Recurrent High-risk Nonâ€“muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. European Urology Open Science, 2022, 39, 14-21.	0.4	7
151	Radiofrequency-Induced Thermo-Chemotherapy Effect (Rite) for Non Muscle Invasive Bladder Cancer Treatment: Current Role and Perspectives. Urologia, 2016, 83, 7-17.	0.7	6
152	External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 239.e9-239.e15.	1.6	6
153	Heterogeneity of risk within Gleason 4â€‰+â€‰4, 4â€‰+â€‰5 and 5â€‰+â€‰4 prostate cancer. Scandinavian Journal of Urology, 2018, 52, 340-348.	1.0	6
154	Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. Clinical Genitourinary Cancer, 2019, 17, e541-e548.	1.9	6
155	Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis. Arab Journal of Urology Arab Association of Urology, 2021, 19, 31-36.	1.5	6
156	Assessment of the oncological outcomes of three different bacillus Calmetteâ€“GuÃ©rin strains in patients with high-grade T1 non-muscle-invasive bladder cancer. Arab Journal of Urology Arab Association of Urology, 2021, 19, 78-85.	1.5	6
157	Postoperative peripheral neuropathies associated with patient positioning during robotâ€assisted laparoscopic radical prostatectomy (RARP): A systematic review of the literature. Prostate, 2021, 81, 361-367.	2.3	6
158	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. Cancer Immunology, Immunotherapy, 2022, 71, 85-95.	4.2	6
159	The Management of Distal Ureter During Radical Nephroureterectomy Does Not Influence Bladder Recurrence. Journal of Endourology, 2022, 36, 77-82.	2.1	6
160	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Molecular Carcinogenesis, 2022, 61, 5-18.	2.7	6
161	Does mpMRI guidance improve HIFU partial gland ablation compared to conventional ultrasound guidance? Early functional outcomes and complications from a single center. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 984-992.	1.5	6
162	A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. Minerva Urology and Nephrology, 2022, 74, .	2.5	6

#	Article	IF	Citations
163	Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence. Current Opinion in Urology, 2022, 32, 69-84.	1.8	6
164	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. Annals of Surgical Oncology, 2022, 29, 5307-5316.	1.5	6
165	Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer. European Urology Oncology, 2022, 5, 722-725.	5.4	6
166	Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. Clinical Genitourinary Cancer, 2017, 15, e223-e228.	1.9	5
167	Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. OncoTargets and Therapy, 2021, Volume 14, 315-324.	2.0	5
168	ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder. , 2017, 37, 5747-5753.		5
169	Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology â€“ Young Academic Urologists. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 195.e27-195.e35.	1.6	5
170	Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 356-362.	1.6	4
171	Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 672.e1-672.e6.	1.6	4
172	Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine. Prostate, 2017, 77, 234-241.	2.3	4
173	The need to improve TURB: a diagnostic and therapeutic fundamental first step in the diseaseâ€™s management. Translational Andrology and Urology, 2019, 8, 2-4.	1.4	4
174	Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes. Urologia Internationalis, 2019, 102, 51-59.	1.3	4
175	Accuracy of MRI-guided Versus Systematic Prostate Biopsy in Patients Under Active Surveillance: A Systematic Review and Meta-analysis. Clinical Genitourinary Cancer, 2021, 19, 3-11.e1.	1.9	4
176	Evaluating the role of neoadjuvant chemotherapy in bladder cancer patients with occult lymph node metastases. Translational Andrology and Urology, 2018, 7, 742-744.	1.4	3
177	Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. European Urology Focus, 2019, 5, 97-103.	3.1	3
178	Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. European Urology, 2020, 77, 1-2.	1.9	3
179	How to improve patient selection for neoadjuvant chemotherapy in bladder cancer patients candidate for radical cystectomy and pelvic lymph node dissection. World Journal of Urology, 2020, 38, 1229-1233.	2.2	3
180	Salvage Radical Prostatectomy After Robot-assisted Laparoscopic Prostatectomy: Case Series. Clinical Genitourinary Cancer, 2020, 18, e202-e207.	1.9	3

#	Article	IF	Citations
181	Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer?. European Urology, 2021, 79, 713-716.	1.9	3
182	Higher nodal yield with robot-assisted pelvic lymph node dissection for bladder cancer compared to laparoscopic dissection: implications for more accurate staging. Arab Journal of Urology Arab Association of Urology, 2021, 19, 92-97.	1.5	3
183	Intravesical Therapy in Patients with Intermediate-risk Nonâ€“muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence. European Urology Focus, 2022, 8, 447-456.	3.1	3
184	Lynch syndrome in urological practice: diagnosis, therapeutic strategies, and screening for upper tract urothelial carcinoma. Current Opinion in Urology, 2022, 32, 40-47.	1.8	3
185	Restaging transurethral resection in ta high-grade nonmuscle invasive bladder cancer: a systematic review. Current Opinion in Urology, 2022, 32, 54-60.	1.8	3
186	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. European Urology Focus, 2022, 8, 972-979.	3.1	3
187	Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer. World Journal of Urology, 2022, 40, 1489-1496.	2.2	3
188	Prognostic impact of insulinâ€like growth factorâ€I and its binding proteins, insulinâ€like growth factorâ€I binding proteinâ€2 and â€3, on adverse histopathological features and survival outcomes after radical cystectomy. International Journal of Urology, 2022, , .	1.0	3
189	The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. Clinical Genitourinary Cancer, 2021, , .	1.9	3
190	The Cancer of the Bladder Risk Assessment (COBRA) score accurately predicts cancer-specific survival after radical cystectomy: external validation and lymphovascular invasion assessment value to improve its performance. Clinical Genitourinary Cancer, 2021, , .	1.9	3
191	The impact of perioperative blood transfusion on survival outcomes in radical cystectomy patients. Translational Andrology and Urology, 2017, 6, 1205-1207.	1.4	2
192	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3091-3102.	2.5	2
193	Robot-assisted radical cystectomy: towards a future of sexual-sparing surgery?. Minerva Urology and Nephrology, 2022, 73, 697-699.	2.5	2
194	The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy. European Urology Open Science, 2022, 41, 74-80.	0.4	2
195	1838 WHEN TO PERFORM LYMPH NODE DISSECTION IN RENAL CELL CARCINOMA PATIENTS: A NOVEL APPROACH TO PREOPERATIVELY ASSESS THE RISK OF LYMPH NODE INVASION AT SURGERY AND NODAL PROGRESSION DURING FOLLOW UP. Journal of Urology, 2013, 189, .	0.4	1
196	RE: Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	1
197	Re: Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial. European Urology, 2018, 74, 119.	1.9	1
198	Adjuvant chemotherapy in bladder cancer patients with histological variants: time to change the approach?. Translational Andrology and Urology, 2019, 8, S280-S282.	1.4	1

#	Article	IF	Citations
199	Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319â€“28. European Urology, 2019, 75, e98-e99.	1.9	1
200	From Basic Science to Clinical Research to Develop New Solutions to Improve Diagnoses and Treatment of Bladder Cancer Patients. Journal of Clinical Medicine, 2020, 9, 2373.	2.4	1
201	Multiparametric magnetic resonance imaging ultrasound-guided fusion biopsy during active surveillance: A single-centre study. Arab Journal of Urology Arab Association of Urology, 2020, 18, 142-147.	1.5	1
202	Single staff cystectomy in a low-volume center: Oncological outcomes and complications. Canadian Urological Association Journal, 2021, 15, E582-E587.	0.6	1
203	The Uro-oncology Patient and Vaccination Against SARS-CoV-2. European Urology Open Science, 2021, 29, 77-81.	0.4	1
204	Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. Immunotherapy, 2021, 13, 917-929.	2.0	1
205	Emerging diagnostic and therapeutic strategies for urothelial carcinoma. Arab Journal of Urology Arab Association of Urology, 2021, 19, 1-1.	1.5	1
206	Is there enough evidence available nowadays to suggest a paradigmatic shift in treatment of MIBC with perioperative systemic therapy administration?. Minerva Urology and Nephrology, 2021, 73, 674-676.	2.5	1
207	Combination of histological and molecular data for improving outcome prediction in non-muscle invasive bladder cancerâ€"narrative review. Translational Cancer Research, 2020, 9, 7323-7336.	1.0	1
208	Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival. Clinical Genitourinary Cancer, 2022, 20, 389.e1-389.e7.	1.9	1
209	Re: Failure-Free Survival and Radiotherapy in Patients with Newly Diagnosed Nonmetastatic Prostate Cancer: Data from Patients in the Control Arm of the STAMPEDE Trial. European Urology, 2016, 70, 398-399.	1.9	0
210	Editorial Comment. Urology, 2017, 103, 147-148.	1.0	0
211	Hospitalization before surgery and subsequent risk of infective complications after radical cystectomy: A population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 659.e7-659.e12.	1.6	0
212	Preoperative Prediction of Node Metastases in Bladder Cancer Patients Using Genomic and Clinicopathologic Data. EBioMedicine, 2018, 31, 5-6.	6.1	0
213	The role of antibiotic prophylaxis after radical cystectomy in preventing urinary tract infections and readmission for sepsis. Translational Andrology and Urology, 2018, 7, 752-753.	1.4	0
214	Re: Kristian D. Stensland, Harras Zaid, Mark Broadwin, et al. Comparative Effectiveness of Treatment Strategies for Squamous Cell Carcinoma of the Bladder. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2018.11.003. European Urology Oncology, 2019, 2, 230.	5.4	0
215	Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319â€“28. European Urology, 2019, 75, e95.	1.9	0
216	CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycinâ€C vs surgical management in lowâ€risk nonâ€muscleâ€invasive bladder cancer. BJU International, 2020, 126, 663-663.	2.5	0

#	Article	IF	Citations
217	Re: Hugh Mostafid, Ashish M. Kamat, Siamak Daneshmand, et al. Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. Eur Urol Oncol 2021;4:12â€“9. European Urology Oncology, 2021, 4, 126.	5.4	0
218	Radical Cystectomy. , 2021, , 139-175.		0
219	Re: Paolo Dellâ€™Oglio, Elio Mazzone, Edward Lambert, et al. The Effect of Surgical Experience on Perioperative and Oncological Outcomes After Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Evidence from a Referral Centre with Extensive Experience in Robotic Surgery. Eur Urol Focus 2021;7:352â€“8. European Urology Focus, 2022, 8, 890.	3.1	0
220	Contemporary Outcomes of Patients With Nonmuscle-Invasive Bladder Cancer Treated With Bacillus Calmette-GuÃ©rin: Implications for Clinical Trial Design. Letter.. Journal of Urology, 2021, 206, 1528.	0.4	0
221	Editorial Comment from Dr Lonati and Dr Moschini to Stage and cancerâ€specific mortality differ within specific Asian ethnic groups in upper tract urothelial carcinoma: North American populationâ€based study. International Journal of Urology, 2021, 28, 1252-1253.	1.0	0
222	Continuing acetylsalicylic acid during Robotic-Assisted Radical Cystectomy with intracorporeal urinary diversion does not increase hemorrhagic complications: results from a large multicentric cohort. Urologic Oncology: Seminars and Original Investigations, 2021, , .	1.6	0
223	Re: Ten-Year Oncologic Outcomes following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. Journal of Urology, 2020, 203, 624-624.	0.4	0
224	Re: Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-GuÃ©rin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. Journal of Urology, 2020, 203, 625-625.	0.4	0
225	Editorial Comment. Journal of Urology, 2020, 204, 32-32.	0.4	0
226	Comment on: Postoperative outcomes of Fast-Track-enhanced recovery protocol in open radical cystectomy: comparison with standard management in a high-volume center and Trifecta proposal. Minerva Urology and Nephrology, 2022, 74, 119-121.	2.5	0
227	ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. Annals of Surgical Oncology, 2022, , 1.	1.5	0
228	Efficacy and toxicity of antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review.. Journal of Clinical Oncology, 2022, 40, e16536-e16536.	1.6	0